Expert Illustrations & Commentaries: A Look into Novel Approaches for the Treatment of Cutaneous and Systemic Lupus Erythematosus

Released On
April 5, 2021

Expires On
April 5, 2022

Media Type

Completion Time
60 minutes



Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Physicians’ Education Resource®, LLC.

This activity is supported by an educational grant from Biogen.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This educational activity is directed toward rheumatologists, internists, dermatologists, specialty nurse practitioners and physician assistants, and primary care physicians engaged in the care of patients with CLE and SLE.

Activity Overview

This Expert Illustrations and Commentaries™ is a video-based program, in which two experts discuss the etiology and management of lupus erythematosus (LE). In this activity, the faculty focus on the pathophysiology, and current and emerging therapeutic strategies for the management of both cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE). Their discussion is enriched with the use of video animations to illustrate the pathophysiology of lupus and the mechanisms of action for some of the emerging therapies to treat patients with this disease. The use of these animated segments helps to make somewhat complicated subject matter more easily understood. This unique format is designed to help clinicians identify best practices in the diagnosis and management of LE and improve outcomes for their patients with this disease.

LE is a chronic-relapsing autoimmune disease with a broad range of cutaneous and systemic symptoms. LE affects people worldwide, with the highest incidence among women of childbearing age and non-White individuals. SLE has a variable presentation and disease course, which could affect every organ. The pattern of clinical manifestations and autoimmune phenomena is heterogeneous among patients and even changes over time in individual patients. Morbidity and mortality for patients with SLE are derived from direct immune-mediated tissue damage and treatment-associated complications, including cardiovascular disease and increased infection risk. In patients with CLE, the body’s immune system attacks healthy skin, causing painful or itchy rashes and skin lesions with severe morbidity.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe the diagnostic criteria for a timely and accurate diagnosis of systemic and cutaneous lupus erythematosus
  • Evaluate standard of care treatment recommendations for the management of patients with systemic and cutaneous lupus erythematosus
  • Analyze the mechanism of action, efficacy, and safety of emerging treatments for systemic and cutaneous lupus erythematosus



Joseph F. Merola, MD, MMSc

Vice Chair, Clinical Trials and Innovation, Department of Dermatology
Director, Clinical Unit for Research Innovation and Trials (CUReIT)
Director, Center for Skin and Related Musculoskeletal Diseases
Associate Program Director, Harvard Combined Internal Medicine-Dermatology Residency
Training Program, Brigham and Women’s Hospital
Associate Professor, Dept. of Dermatology and Dept. of Medicine, Division of Rheumatology,
Harvard Medical SchoolBoston, MA


Victoria P. Werth, MD

Professor of Dermatology, University of Pennsylvania
Chief of Dermatology, Corporal Michael J. Crescenz VAMC
University of Pennsylvania School of Medicine
Philadelphia, PA

Physician Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

In accordance with ACCME guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Joseph F. Merola, MD, MMSc

  • Consultant: AbbVie, Amgen, Bayer, Biogen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi-Regeneron, and UCB
  • Investigator: Dermavant, LEO Pharma, Sanofi, UCB.

Victoria P. Werth, MD

  • Consulting: AbbVie, Amgen, AstraZeneca, Beacon Bioscience, Biogen, Bristol Myers Squibb, Celgene, Corcept, CSL Behring, Cugene, EMD Serono, Gilead, GSK, Janssen, Kirin, Lilly, Pfizer, Resolve, UCB, Viela Bio
  • Grants: Amgen, AstraZeneca, Biogen, Celgene, Corbus Pharmaceuticals, Gilead, Janssen, Pfizer, Syntimmune, Viela
  • University of Pennsylvania owns the copyright for the CLASI.

The staff of Physicians’ Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.